Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 19Rectal Neoplasms 10Colonic Neoplasms 10Pancreatic Neoplasms 3Neoplasm Metastasis 3Carcinoma, Hepatocellular 3Unspecified Adult Solid Tumor, Protocol Specific 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Sarcoma 1Retinoblastoma 1Pancreatic Adenocarcinoma Metastatic 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms 1Mycosis Fungoides 1Motor Activity 1Melanoma 1Malignant Tumor of Pancreas Metastatic to Liver 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Immunoblastic Lymphadenopathy 1Gastrointestinal Neoplasms 1

Interventions

irinotecan sucrosofate 1Leucovorin 1Gemcitabine 1Fluorouracil 1Capecitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Malignant Tumor of Pancreas Metastatic to Liver × Leucovorin × Clear all
NCT04037241 2022-04-01

Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases

Sorrento Therapeutics, Inc.

Phase 2/3 Withdrawn
Gastrointestinal

Malignant Tumor of Pancreas Metastatic to Liver

Data powered by HemOnc (CC BY 4.0) Colophon âš¡